These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37268051)

  • 1. Tocilizumab for antibody-mediated rejection treatment in lung transplantation.
    January SE; Fester KA; Halverson LP; Witt CA; Byers DE; Vazquez-Guillamet R; Alexander-Brett J; Tague LK; Kreisel D; Gelman A; Puri V; Bahena RN; Takahashi T; Hachem RR; Kulkarni HS
    J Heart Lung Transplant; 2023 Oct; 42(10):1353-1357. PubMed ID: 37268051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
    Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
    Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
    Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
    Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
    Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
    Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
    Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
    Front Immunol; 2022; 13():839380. PubMed ID: 35493469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-empting Antibody-Mediated Rejection: A Program of DSA Monitoring and Treatment Can Effectively Prevent Antibody Mediated Rejection.
    Gilbert A; Grafals M; Timofeeva O; Zaheer M; Karabala A; Rosen-Bronson S; Li D; Awwad M; Abrams P; Moore J; Javaid B; Verbesey J; Ghasemian S; Cooper M
    Clin Transpl; 2016; 32():93-101. PubMed ID: 28564526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study.
    Kovandova B; Slavcev A; Honsova E; Erhartova D; Skibova J; Viklicky O; Trunecka P
    Transpl Int; 2020 Dec; 33(12):1799-1806. PubMed ID: 33020979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.